Mixed HCV Infection of Genotype 1B and Other Genotypes Influences Non-response during Daclatasvir + Asunaprevir Combination Therapy.

doi:10.18926/AMO/56178

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Mixed HCV Infection of Genotype 1B and Other Genotypes Influences Non-response during Daclatasvir + Asunaprevir Combination Therapy.

Acta medica Okayama - 1 Aug 2018

Wada Nozomu, Ikeda Fusao, Mori Chizuru, Takaguchi Koichi, Fujioka Shin-Ichi, Kobashi Haruhiko, Morimoto Yoichi, Kariyama Kazuya, Sakaguchi Kosaku, Hashimoto Noriaki, Moriya Akio, Kawaguchi Mitsuhiko, Miyatake Hirokazu, Hagihara Hiroaki, Kubota Junichi, Takayama Hiroki, Takeuchi Yasuto, Yasunaka Tetsuya, Takaki Akinobu, Iwasaki Yoshiaki, Okada Hiroyuki

Abstract excerpt

Daclatasvir (DCV) + asunaprevir (ASV) combination therapy has become available for patients with hepatitis C virus (HCV) serogroup 1 infection. We studied the efficacy of this therapy by focusing on the factors associated with sustained virological responses (SVR) including resistance-associated variants (RAVs) and mixed infection of different HCV genotypes. We enrolled 951 HCV serogroup 1-positive patients who...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carbamates

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Therapy, Combination

Share to Hepatitis C

Share to Imidazoles

Share to Isoquinolines

Share to Pyrrolidines

Share to Sulfonamides

Share to Valine

Source

Open in PubMed

Identifiers

PMID: 30140089
DOI: 10.18926/AMO/56178

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Mixed HCV Infection of Genotype 1B and Other Genotypes Influences Non-response during Daclatasvir + Asunaprevir Combination Therapy.PMID 30140089Read ↗

Effectiveness and safety of daclatasvir plus asunaprevir for hepatitis C virus genotype 1b: Systematic review and meta-analysis.Semantic proximity Read ↗

Efficacy of daclatasvir/asunaprevir according to resistance-associated variants in chronic hepatitis C with genotype 1.Semantic proximity Read ↗

Low frequency of drug-resistant virus did not affect the therapeutic efficacy in daclatasvir plus asunaprevir therapy in patients with chronic HCV genotype-1 infection.Semantic proximity Read ↗

Daclatasvir and asunaprevir combination therapy for patients with chronic hepatitis C virus genotype 1b infection in real world.Semantic proximity Read ↗

Efficacy and safety of daclatasvir and asunaprevir for hepatitis C virus genotype 1b infection.Semantic proximity Read ↗

Pooled analysis of HCV genotype 1 resistance-associated substitutions in NS5A, NS3 and NS5B pre-and post-treatment with 12 weeks of daclatasvir, asunaprevir and beclabuvir.Semantic proximity Read ↗

Beclabuvir in combination with asunaprevir and daclatasvir for hepatitis C virus genotype 1 infection: A systematic review and meta-analysis.Semantic proximity Read ↗

Pangenotypic direct-acting antiviral agents for mixed genotype hepatitis C infection: A real-world effectiveness analysis.Semantic proximity Read ↗

Daclatasvir plus Asunaprevir Treatment for Real-World HCV Genotype 1-Infected Patients in Japan.Semantic proximity Read ↗

Impact of resistance-associated variant dominancy on treatment in patients with HCV genotype 1b receiving daclatasvir/asunaprevir.Semantic proximity Read ↗

Daclatasvir plus asunaprevir in treatment-naïve patients with hepatitis C virus genotype 1b infection.Semantic proximity Read ↗

Daclatasvir plus simeprevir with or without ribavirin for the treatment of chronic hepatitis C virus genotype 1 infection.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.